Clinical trials: Pancreatic Beta Cell Function
Type 2 Diabetes
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.
- Trial name
- NCT02386982
- Testing
- HMS5552
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hua Medicine Limited
Coronary Artery Disease, Diabetes Mellitus, Type 2
The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes
The purpose of this study is to investigate the effect of combined glucagon-like-peptide-1 (GLP-1) analogue and metformin therapy on glucose metabolic and cardiovascular endpoints compared to metformin monotherapy in patients…
- Trial name
- AddHope2 (NCT01595789)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 41 people
- Sponsor
- Haugaard, Steen Bendix, M.D., DMSc
Gestational Diabetes
Can Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?
The purpose of this study is to determine if resveratrol supplementation preserves beta cell function and insulin sensitivity in post-partum women following a first diagnosis of gestational diabetes.
- Trial name
- NCT01997762
- Testing
- Resveratrol
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Type 1 Diabetes Mellitus
Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes
This clinical study will evaluate the safety of an innovative approach expected to be disease-modifying by stopping the auto-immune-mediated destruction of islet β-cells in the pancreas.
- Trial name
- NCT03272269
- Testing
- IMCY-0098
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 41 people
- Sponsor
- Imcyse SA
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Turner Syndrome
Risk of Diabetes in Young Turner Syndrome Patients
Turner Syndrome is a common genetic disorder. Seventy percent of adults with Turner Syndrome have abnormalities in glucose metabolism which can lead to diabetes.
- Trial name
- NCT02160717
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Obesity, Insulin Resistance
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)
The undercarboxylated fractions of the two vitamin K-dependent proteins osteocalcin and matrix Gla protein have been shown to play key roles in type 2 diabetes and cardiovascular disease (at least in mouse models).
- Conditions
- Obesity, Insulin Resistance, Insulin Sensitivity, Prediabetes
- Trial name
- NCT01972113
- Testing
- Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Augusta University
Type 1 Diabetes
Denosumab for Type 1 Diabetes
Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy.
- Trial name
- NCT06524960
- Testing
- Denosumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- City of Hope Medical Center
Fatty Liver, Insulin Resistance
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin…
- Trial name
- NCT00252499
- Testing
- rosiglitazone, fenofibrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
COVID19, BETA-CELL FUNCTION
Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients
In recent months, a new coronavirus, SARS-CoV-2, has been identified as the cause of a serious lung infection named COVID-19 by the World Health Organization.
- Trial name
- COBETOX (NCT04463849)
- Testing
- Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Milan
Type1diabetes, Type2diabetes
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus
The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass…
- Conditions
- Type1diabetes, Type2diabetes, Pre Diabetes, Hyperinsulinism
- Trial name
- NCT05662189
- Testing
- 68Ga-exendin-4, mixed meal test
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Obesity, Type 2 Diabetes
Role of Pancreatic Triglyceride Content in Beta-cell Function
The study evaluates if fat accumulates in the pancreas in individuals at risk of developing obesity-related diabetes. It also evaluates if the amount of fat in the pancreas can predict the residual functional capacity of the…
- Trial name
- NCT00602953
- Testing
- No intervention planned.
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 1
Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients
The present proof of concept study addresses the following specific aims: The general objectives of this work are: 1. To increase and maintain the functional beta-cell mass after islet transplantation under a condition of…
- Trial name
- NCT00798785
- Testing
- ATG-MMF-TAC, ATG-Rituximab-MMF-TAC, ATG-basilixumab-MMF-TAC
- Where
- 4 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- Universitair Ziekenhuis Brussel
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus
Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the…
- Conditions
- Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
- Trial name
- EXTEND (NCT02293837)
- Testing
- Tocilizumab (TCZ), Standard of Care
- Where
- 19 sites in United States, Australia
- Volunteers
- 136 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 2 Diabetes Mellitus
Glucolipotoxicity and Type 2 Diabetes
Elevations of blood glucose and lipid are thought to be deleterious to the insulin secretory function of the pancreas. This is known as glucolipotoxicity. However, few studies have examined this in detail.
- Trial name
- NCT01375270
- Testing
- Glucotoxicity, Lipotoxicity
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Type 2 Diabetic Patients, Insufficient Metabolic Control
Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin
The aim of the study is to show that treatment with Glargine will lead to an improvement in beta cell function especially within times of maximal beta cell stress occurring after a meal.
- Conditions
- Type 2 Diabetic Patients, Insufficient Metabolic Control, OAD Treatment
- Trial name
- NCT00941148
- Testing
- Insulin Glargin, NPH insulin, Insulin detemir
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- ikfe-CRO GmbH
Type 1 Diabetes, Diabetes Mellitus, Type 1
Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes
The goal of this clinical trial is to test whether the combination of two safe immune therapies called abatacept and nasal insulin can preserve pancreas function in recently-diagnosed type 1 diabetes.
- Trial name
- IAA (NCT05742243)
- Testing
- Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)
- Where
- 6 sites in Australia
- Volunteers
- 68 people
- Sponsor
- Melbourne Health
Diabetes Mellitus, Type 1
Verapamil SR in Adults With Type 1 Diabetes
This study has been set up within the framework of the INNODIA network. INNODIA is a global partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise and 2 patient organizations, bringing their…
- Trial name
- Ver-A-T1D (NCT04545151)
- Testing
- Verapamil SR 120 mg
- Where
- 22 sites in Austria, Belgium and 4 more
- Volunteers
- 136 people
- Sponsor
- Medical University of Graz
Prediabetes
Effect of Resistant Starch on Insulin Sensitivity and Beta Cell Function in Subjects With Prediabetes
To compare the use supplementation based on green banana flour versus placebo in the insulin sensitivity on individuals who have prediabetes.
- Trial name
- NCT03294915
- Testing
- Resistant Starch
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Diabetes Mellitus, Type 1
A Research Trial of Aralast in New Onset Diabetes (RETAIN)
The drug Alpha-1 Antitrypsin (AAT, Aralast NP) is being tested in this study as an anti-inflammatory drug (a medication that decreases inflammation, which is part of the body's normal ability to fight infection and respond to…
- Trial name
- RETAIN (NCT01183468)
- Testing
- Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
- Where
- 15 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)